Literature DB >> 10824888

Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.

T Itoh1, Y Hayashi, T Kanamaru, Y Morita, S Suzuki, W Wang, L Zhou, J A Rui, M Yamamoto, Y Kuroda, H Itoh.   

Abstract

BACKGROUND AND METHODS: The plasminogen activation system plays a crucial role in the process of cancer invasion and metastasis. To evaluate the most effective factor in the invasion, metastasis and prognosis of hepatocellular carcinoma (HCC), we examined urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor (PAI)-1, PAI-2 and uPA activity by enzyme-linked immunosorbent assays (ELISA) in HCC tissues obtained from 46 patients. The results were compared with the patients' clinicopathological features and prognoses.
RESULTS: Of the clinicopathological features, only histological portal involvement or intrahepatic metastasis, or both (INV), was significantly correlated to the disease-free survival rates (DFS; P < 0.05). The levels of uPA, PAI-1 and PAI-2 antigens were significantly associated with INV and histological grade. The DFS was not different, however, between cases with uPA, PAI-1 and PAI-2 values above and below the median. The high levels of uPA activity were closely related to INV (P < 0.001), and the activity gradually raised histological grades (P < 0.0001). The DFS was significantly different between patients with uPA activity below and above the median (0.70 ng/mL; P = 0.0092); it was also significantly different between such patients without INV (P < 0.05).
CONCLUSIONS: Urokinase-type plasminogen activator activity may be the most sensitive factor affecting HCC invasion in the plasminogen activation system and a strong predictor for the recurrence of HCC. We suggest that cases with uPA activity of more than 0.70 ng/mL should be carefully followed up for possible HCC recurrence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10824888     DOI: 10.1046/j.1440-1746.2000.02150.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

1.  Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver.

Authors:  J G Fan; L H Chen; Z J Xu; M D Zeng
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 2.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

3.  Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.

Authors:  Chin-Shiu Huang; Shih-Chieh Lyu; Miao-Lin Hu
Journal:  Invest New Drugs       Date:  2011-08-09       Impact factor: 3.850

4.  Proteinases and their inhibitors in liver cancer.

Authors:  Verena Puxbaum; Lukas Mach
Journal:  World J Hepatol       Date:  2009-10-31

Review 5.  The prognostic molecular markers in hepatocellular carcinoma.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.

Authors:  Da-Eun Nam; Angelina Angelucci; Dahsom Choi; Arnold Leigh; Hae Chang Seong; Young S Hahn
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

Review 7.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

8.  Secretome profiling of oral squamous cell carcinoma-associated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures.

Authors:  Elizabete Bagordakis; Iris Sawazaki-Calone; Carolina Carneiro Soares Macedo; Carolina M Carnielli; Carine Ervolino de Oliveira; Priscila Campioni Rodrigues; Ana Lucia C A Rangel; Jean Nunes Dos Santos; Juha Risteli; Edgard Graner; Tuula Salo; Adriana Franco Paes Leme; Ricardo D Coletta
Journal:  Tumour Biol       Date:  2016-01-13

9.  Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma.

Authors:  Li Zhou; Ye Jin; Quan-Cai Cui; Ke-Min Jin; Wei-Xun Zhou; Bao-Cai Xing
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

Review 10.  The contact system in liver injury.

Authors:  Chandini Rangaswamy; Reiner K Mailer; Hanna Englert; Sandra Konrath; Thomas Renné
Journal:  Semin Immunopathol       Date:  2021-06-14       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.